Abstract 14700: Atorvastatin Safety and Pharmacokinetics in Acute Kawasaki Disease Patients With Coronary Artery Abnormalities
Adriana H. Tremoulet(George Washington University Hospital), Jane C. Burns(Rady Children's Hospital-San Diego), Pei‐Ni Jone(Northwestern University), Ming He, Feng He(Air Force Medical University), John C. Whitin(Dartmouth College), Alessandra Franco(University of California San Diego), Heather Heizer, Brookie M. Best, Sonia Jain(Mayo Clinic), Chisato Shimizu(University of California San Diego), Negar Behnamfar, Samuel R. Dominguez(Children's Hospital Colorado), Mary P. Glodé, Harvey J. Cohen(Lucile Packard Children's Hospital), Beth F. Printz(Columbia University Irving Medical Center), Marsha S. Anderson(Children's Hospital Colorado), Elizabeth Duxbury(University of California San Diego)
Circulation
November 14, 2017
Cited by 0
Related Papers
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
|Circulation|2017|3.7k
Prevention of Infective Endocarditis
|Circulation|2007|2.8k
A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki Syndrome
|New England Journal of Medicine|1991|1.2k
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1
|Arthritis & Rheumatology|2020|537
Prevention of infective endocarditis: Guidelines from the American Heart Association
|The Journal of the American Dental Association|2008|484